Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allakos Inc. stock logo
ALLK
Allakos
$0.33
$0.33
$0.22
$1.56
$29.74M0.151.24 million shsN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
$3.96
-5.0%
$3.27
$1.98
$66.60
$12.01M0.3205,954 shs417,623 shs
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
$20.31
-12.6%
$10.44
$4.56
$76.00
$80.95M0.19244,710 shs677,478 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.42
-0.3%
$0.56
$0.39
$3.75
$26.27M-0.021.15 million shs1.07 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allakos Inc. stock logo
ALLK
Allakos
0.00%0.00%0.00%+0.95%-60.04%
CEL-SCI Co. stock logo
CVM
CEL-SCI
-5.04%+12.18%+72.93%-48.19%-90.70%
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
-12.65%-68.35%+173.35%+166.19%+93.43%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-0.31%-35.47%-18.19%-64.48%-88.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allakos Inc. stock logo
ALLK
Allakos
3.4024 of 5 stars
3.20.00.04.70.02.51.3
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.1215 of 5 stars
0.02.00.00.00.60.00.6
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
2.7936 of 5 stars
3.43.00.00.02.81.70.6
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.3671 of 5 stars
3.51.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allakos Inc. stock logo
ALLK
Allakos
2.33
Hold$3.00811.58% Upside
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
2.75
Moderate Buy$37.5084.64% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,664.52% Upside

Current Analyst Ratings Breakdown

Latest CVM, RANI, ALLK, and INKT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/15/2025
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral$35.00
7/11/2025
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/16/2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/A$1.93 per shareN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
N/AN/AN/AN/A($4.94) per shareN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.03M25.50N/AN/A$0.06 per share6.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allakos Inc. stock logo
ALLK
Allakos
-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/A
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
-$9.51M-$2.520.00N/AN/AN/AN/A-140.72%8/12/2025 (Estimated)
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.990.00N/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)

Latest CVM, RANI, ALLK, and INKT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
-$0.45N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Allakos Inc. stock logo
ALLK
Allakos
-$0.24N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.19N/AN/AN/AN/AN/A
5/15/2025Q1 2025
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
-$0.61-$0.70-$0.09-$0.70N/AN/A
5/13/2025Q1 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.22-$0.22N/A-$0.22N/A$0.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allakos Inc. stock logo
ALLK
Allakos
N/A
6.08
6.08
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
N/A
0.30
0.30
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.88
0.88

Institutional Ownership

CompanyInstitutional Ownership
Allakos Inc. stock logo
ALLK
Allakos
84.64%
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
2.87%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%

Insider Ownership

CompanyInsider Ownership
Allakos Inc. stock logo
ALLK
Allakos
16.12%
CEL-SCI Co. stock logo
CVM
CEL-SCI
9.93%
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
22.48%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
45.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allakos Inc. stock logo
ALLK
Allakos
19090.38 million74.94 millionOptionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
433.03 million64.67 millionOptionable
MiNK Therapeutics, Inc. stock logo
INKT
MiNK Therapeutics
303.99 million3.09 millionNo Data
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11063.21 million34.71 millionOptionable

Recent News About These Companies

Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance
Rani Therapeutics strikes deal to issue new warrants
RANI: 1Q:25 Financial Results
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street
RANI: 2024 Financial Results
Q4 2024 Rani Therapeutics Holdings Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allakos stock logo

Allakos NASDAQ:ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$3.96 -0.21 (-5.04%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.97 +0.01 (+0.25%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

MiNK Therapeutics stock logo

MiNK Therapeutics NASDAQ:INKT

$20.31 -2.94 (-12.65%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$20.82 +0.52 (+2.54%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.42 0.00 (-0.31%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.41 0.00 (-0.63%)
As of 07/18/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.